Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
Icca Revenue: $66 million, 100% growth since Q3 2023. Icca Market Share: Nearly 30% share, maintaining the number two position. Lact Sales: $5.8 million in Q3, a 54% increase quarter over quarter. Cost of Goods Sold: $20.7 million, down $12 million from Q3 last year. Gross Profit Improvement: 20% improvement or $8.2 million. R&D Expense: $21.7 million, a decrease of 15% from Q3 a year ago. SG&A Expense: $34.7 million, a decrease of 28% compared to the prior year. Interest Expense: $5.4 million, a decrease of 48% from Q3 last year. Net Loss: $10.8 million or 9 per diluted share. Non-GAAP Net Loss: $1.7 million or 1 per diluted share. Cash and Investments: $97.7 million as of September 30, 2024. 2024 Expense Guidance: Combined R&D and SG&A expenses expected to be $250 million to $260 million. Warning! GuruFocus has detected 5 Warning Signs with CHRS. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full ea
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 11/6/24 - Beat
CHRS
Sec Filings
- 11/13/24 - Form SC
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- CHRS's page on the SEC website